Altoida, Inc. news and updates
Altoida, Inc. partnered with GN Group on Feb 1st 22'.
In February 2022, Altoida announced a multi-year strategic partnership with GN Group, a global leader in intelligent audio solutions and manufacturer of ReSound hearing aids.
Jan 1, 2022 | prnewswire.comAltoida, Inc. received financing of $14M in Series A round on Mar 30th 22'.
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors.
Jan 1, 2022 | businesswire.comAltoida, Inc. received financing of $20.3M in Series A funding on Feb 28th 22'.
Altoida, a D.C.-based neurology assessment company that recently raised $20.3 million in Series A funding, uses AI and augmented reality (AR) technology to upgrade conventional neurocognitive assessments.
Jan 1, 2022 | builtin.comLenihan leaves Altoida, Inc. as Vice President of Operations
Lenihan joins PMI from Altoida, Inc., a medical device company that uses AI and AR to predict neurological disease, where she served as Vice President of Operations.
Jan 1, 2022 | businesswire.comAltoida, Inc. partnered with DIME Society on May 16th 22'.
Altoida, a pioneer in non-invasive brain health measurement and neurological disease diagnostics using AI and augmented reality (AR), today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project to support the advancement of its precision neuro-biomarkers platform.
Jan 1, 2022 | bdtonline.comAltoida, Inc. partnered with Click Therapeutics, Inc. on Feb 1st 22'.
Altoida, Inc. an artificial intelligence (AI) company pioneering next-generation neurological disease diagnostics, announced today a partnership with Click Therapeutics, a leader in Digital Therapeutics™ as prescription medical treatments, to bring more sensitive measures of cognition into their digital therapeutics research.
Jan 1, 2022 | businesswire.comAltoida, Inc. hired Antonella Santuccione Chadha as Chief Medical Officer on May 31st 22'.
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer.
Jan 1, 2022 | businesswire.comAltoida, Inc. is developing software platform
Altoida is developing a software platform that uses artificial intelligence and augmented reality to evaluate an individual’s brain health, with an initial focus on predicting the likelihood that a case of mild cognitive impairment will escalate to Alzheimer’s within a year.
Jan 1, 2022 | fiercebiotech.com